Repare Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $9.2
- Today's High:
- $10.34
- Open Price:
- $9.8
- 52W Low:
- $8.02
- 52W High:
- $18.68
- Prev. Close:
- $9.93
- Volume:
- 144159
Company Statistics
- Market Cap.:
- $406.63 million
- Book Value:
- 5.83
- Revenue TTM:
- $166.67 million
- Operating Margin TTM:
- 4.1%
- Gross Profit TTM:
- $15.11 million
- Profit Margin:
- -1.85%
- Return on Assets TTM:
- 1.4%
- Return on Equity TTM:
- -1.31%
Company Profile
Repare Therapeutics Inc had its IPO on 2020-06-19 under the ticker symbol RPTX.
The company operates in the Healthcare sector and Biotechnology industry. Repare Therapeutics Inc has a staff strength of 180 employees.
Stock update
Shares of Repare Therapeutics Inc opened at $9.8 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $9.2 - $10.34, and closed at $9.38.
This is a -5.54% slip from the previous day's closing price.
A total volume of 144,159 shares were traded at the close of the day’s session.
In the last one week, shares of Repare Therapeutics Inc have slipped by -2.9%.
Repare Therapeutics Inc's Key Ratios
Repare Therapeutics Inc has a market cap of $406.63 million, indicating a price to book ratio of 2.0392 and a price to sales ratio of 5.1987.
In the last 12-months Repare Therapeutics Inc’s revenue was $166.67 million with a gross profit of $15.11 million and an EBITDA of $8.71 million. The EBITDA ratio measures Repare Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Repare Therapeutics Inc’s operating margin was 4.1% while its return on assets stood at 1.4% with a return of equity of -1.31%.
In Q2, Repare Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 4354.9%.
Repare Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.06 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Repare Therapeutics Inc’s profitability.
Repare Therapeutics Inc stock is trading at a EV to sales ratio of 2.15 and a EV to EBITDA ratio of -9.5934. Its price to sales ratio in the trailing 12-months stood at 5.1987.
Repare Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $301.59 million
- Total Liabilities
- $53.25 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $1.07 million
- Dividend Payout Ratio
- 0%
Repare Therapeutics Inc ended 2024 with $301.59 million in total assets and $0 in total liabilities. Its intangible assets were valued at $301.59 million while shareholder equity stood at $245.41 million.
Repare Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $53.25 million in other current liabilities, 482739000.00 in common stock, $-286200000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $115.54 million and cash and short-term investments were $280.69 million. The company’s total short-term debt was $2,320,000 while long-term debt stood at $0.
Repare Therapeutics Inc’s total current assets stands at $291.93 million while long-term investments were $0 and short-term investments were $165.15 million. Its net receivables were $7.03 million compared to accounts payable of $4.89 million and inventory worth $-1751000.00.
In 2024, Repare Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $1.07 million.
Comparatively, Repare Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $9.38
- 52-Week High
- $18.68
- 52-Week Low
- $8.02
- Analyst Target Price
- $26.88
Repare Therapeutics Inc stock is currently trading at $9.38 per share. It touched a 52-week high of $18.68 and a 52-week low of $18.68. Analysts tracking the stock have a 12-month average target price of $26.88.
Its 50-day moving average was $9.92 and 200-day moving average was $11.24 The short ratio stood at 13.59 indicating a short percent outstanding of 0%.
Around 102.6% of the company’s stock are held by insiders while 8818.8% are held by institutions.
Frequently Asked Questions About Repare Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company’s lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.